GlassScriptPhysician profile
Morgan Hurta
NPI 1417663808
$1,814.90
in general payments reported to CMS, 2019-2025
14 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $503 · 2024: $410 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.54 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $255.84 | 2023-2025 | |
| Axonics, INC. | $235.42 | 2023 | Axonics |
| Sumitomo Pharma America, INC. | $171.74 | 2023-2025 | Gemtesa, Myfembree |
| Biogen, INC. | $131.18 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $75.75 | 2025 | Slynd |
| Organon LLC | $67.05 | 2024-2025 | Nexplanon |
| Shield Therapeutics INC | $60.84 | 2023-2025 | Accrufer |
| Coopersurgical, INC. | $46.21 | 2024-2025 | Paragard T 380a |
| Millicent US INC | $36.59 | 2023-2025 | Intrarosa, Femring |
| Pfizer INC. | $34.44 | 2023-2024 | |
| Boston Scientific Corporation | $21.02 | 2025 | Axonics |
| Astellas Pharma US INC | $18.73 | 2025 | Veozah |
| Evofem Biosciences, INC. | $9.55 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hurta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.